[GLP-1 derivatives, for the prevention and treatment of type 2 diabetes mellitus].
Namba
Mitsuyoshi
M
Hyogo College of Medicine, The Division of Diabetes and Metabolism, The Department of Internal Medicine.
Miyagawa
Juh-ichiro
J
Hamaguchi
Tomoya
T
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control*; D004285:Dogs; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000502:physiology / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D024821:Metabolic Syndrome / Q000150:complications; D009765:Obesity / Q000378:metabolism; D010455:Peptides / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
D007328:Insulin; D010455:Peptides; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide